Global Response Aid (GRA), an affiliate of Agility, announced that a Phase 3 US-Canada clinical trial of Avigan®, an anti-viral drug, will continue amid signs the drug could be effective in treatment of patients with mild to moderate cases of COVID-19.
Interim results of the trials indicate that Avigan®, the brand name for generic Favipiravir, could shorten recovery times and prevent progression of COVID-19 in patients in early stages of infection. The US-Canada clinical trial will continue into the summer.
Dubai-based GRA holds joint rights to manufacture, market and distribute Avigan® outside of Japan, China and Russia.

There is no material impact as yet because the drug is not licensed or approved for treatment of COVID-19 in the United States or Canada.


Investor Relations Team